Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: Position paper of an International Consortium and the European LeukemiaNet Working Group

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 472-475

  Van De Loosdrecht, Arjan A ^a   Ireland, Robin ^b   Kern, Wolfgang ^c   Della Porta, Matteo G ^d   Alhan, Canan ^a   Balleisen, Jan Sebastian ^e   Bettelheim, Peter ^f   Bowen, David T ^g   Burbury, Kate ^h   Eidenschink, Lisa ⁱ   Cazzola, Mario ^d   Chu, Spencer S C ^j   Cullen, Matthew ^g   Cutler, Jevon A ⁱ   Dräger, Angelika M ^a   Feuillard, Jean ^k   Fenaux, Pierre ^l   Font, Patricia ^m   Germing, Ulrich ^e   Haase, Detlef ⁿ   Hellström Lindberg, Eva ^o   Johansson, Ulrika ^p   Kordasti, Shahram ^b   Loken, Michael R ⁱ   Malcovati, Luca ^d   Te Marvelde, Jeroen G ^q   Matarraz, Sergio ^r   Milne, Timothy ^b   Moshaver, Bijan ^s   Mufti, Ghulam J ^b   Nikolova, Veselka ^t   Ogata, Kiyoyuki ^u   Oelschlaegel, Uta ^v   Orfao, Alberto ^r   Ossenkoppele, Gert J ^a   Porwit, Anna ^o   Platzbecker, Uwe ^v   Preijers, Frank ^s   Psarra, Katherina ^w   Richards, Stephen J ^g   Subirá, Dolores ^x   Seymour, John F ^h   Tindell, Vicky ^b   Vallespi, Teresa ^y   Valent, Peter ^z   Van Der Velden, Vincent H J ^q   Wells, Denise A ⁱ   De Witte, Theo M ^s   Zettl, Florian ⁿ   Béné, Marie C ^aa   Westers, Theresia M ^a   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY OF PAVIA   (Italy)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f ELISABETHINEN HOSPITAL   (Austria)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ HEMATOLOGICS INC   (United States)

^j TZU CHI UNIVERSITY   (Taiwan)

^k DUPUYTREN UNIVERSITY HOSPITAL   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁿ UNIVERSITY OF GÖTTINGEN   (Germany)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r UNIVERSITY OF SALAMANCA   (Spain)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^t National Specialized Hospital for Active Treatment of Hematological Diseases   (Bulgaria)

^u NIPPON MEDICAL SCHOOL   (Japan)

^v UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^w EVANGELISMOS HOSPITAL   (Greece)

^x HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^y HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^z MEDICAL UNIVERSITY OF VIENNA   (Austria)

^aa UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Consensus; ELN; Flow cytometry; Myelodysplastic syndromes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; ERYTHROPOIETIN; GROWTH FACTOR; LACTATE DEHYDROGENASE;

ACUTE MYELOBLASTIC LEUKEMIA; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY THROMBOCYTOPENIA; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE; TRISOMY 8; WORLD HEALTH ORGANIZATION;

FLOW CYTOMETRY; HUMANS; INTERNATIONAL AGENCIES; MYELODYSPLASTIC SYNDROMES; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOCIETIES, SCIENTIFIC;

EID: 84873396563     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.718341     Document Type: Review

References (41)

1. Valent P, Horny HP, Bennett JM, et al. definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31: 727-736.
2. van de Loosdrecht AA, Alhan C, Bene MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European Leukemia Net working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94: 1124-1134.
3. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European Leukemia Net Working Group. Leukemia 2012;26: 1730-1741.
4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100: 2292-2302.
5. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23: 7594-7603.
6. van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low-and intermediate-1-risk myelodysplastic syndromes by fow cytometry. Blood 2008;111: 1067-1077.
7. Stachurski D, Smith BR, Pozdnyakova O, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specif c in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008;32: 215-224.
8. Brunning R, Orazi A, Germing U, et al. Myelodysplasticsyndromes/ neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours and haematopoietic and lymphoid tissues. Lyon: IARC: 2008. pp 88-147.
9. Wimazal F, Fonatsch C, Talhammer R, et al. Idiopathic cytopenia of undetermined signif cance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007: 31: 1461-1468.
10. Valent P, Horny HP. Minimal diagnostic criteria for myelodys-plastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009;39: 548-553.
11. Truong F, Smith BR, Stachurski D, et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009: 33: 1039-1046.
12. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009: 94: 1066-1074.
13. Della Porta MG, Ogata K, Picone C, et al. Multicentric validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 2012;97: 1209-1217.
14. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102: 394-403.
15. Ogata K, Kishikawa Y, Satoh C, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006;108: 1037-1044.
16. Scott BL, Wells DA, Loken MR, et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008;112: 2681-2686.
17. Matarraz S, Lopez A, Barrena S, et al. The immunophenotype of Different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008;22: 1175-1183.
18. Matarraz S, Lopez A, Barrena S, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on A series of 56 patients. Cytometry B Clin Cytom 2010;78: 154-168.
19. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30: 820-829.
20. Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012 Jun 27. [Epub ahead of print]
21. Germing U, Hildebrandt B, Pfeilstocker M, et al. Ref nement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005;19: 2223-2231.
22. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007: 25: 3503-3510.
23. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009: 41: 838-842.
24. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42: 665-667.
25. Valent P, Orazi A, Busche G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 2010;1: 483-496.
26. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96: 441-449.
27. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011;29: 1963-1970.
28. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway muta-tions of splicing machinery in myelodysplasia. Nature 2011: 478: 64-69.
29. Bejar R, Stevenson K, Bdel-Wahab O, et al. Clinical Effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011: 364: 2496-2506.
30. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical signif cance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/ myeloproliferative neoplasms. Blood 2011: 118: 6239-6246.
31. Cutler JA, Wells DA, van de Loosdrecht AA, et al. Phenotypic abnormalities strongly rEffect genotype in patients with unexplained cytopenias. Cytometry B Clin Cytom 2011;80: 150-157.
32. Kern W, Haferlach C, Schnittger S, et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010;116: 4549-4563.
33. Chu SC, Wang TF, Li CC, et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011;35: 868-873.
34. Kordasti SY, Ingram W, Hayden J, et al. CD4+ CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110: 847-850.
35. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109: 4816-4824.
36. Chamuleau ME, Westers TM, van Dreunen L, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009;94: 496-506.
37. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(+) T cells, pro-inf ammatory cytokines and apoptosis are increased in lowrisk myelodysplastic syndrome. Br J Haematol 2009;145: 64-72.
38. Westers TM, Alhan C, Chamuleau MED, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010;115: 1779-1784.
39. Frisan E, Pawlikowska P, Pierre-Eugene C, et al. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica 2010;95: 1964-1968.
40. Westers TM, Alhan C, Cali C, et al. Quantitative dynamics of flow cytometric aberrancies during treatment with erythropoietin/G-CSflare predictive for responses in low/Int-1 risk myelodysplastic syndromes. Blood 2008: 112(Suppl. 1): Abstract 586.
41. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011: 117: 2697-2702.